Overview
Avadim Health develops and markets topical healthcare and wellness products, using its Bionome Engineered Platform to create non-prescription therapies and manage development, manufacturing, and marketing in-house. Its Theraworx line includes Theraworx Relief for muscle cramps, joint pain, and nerve discomfort, and Theraworx Protect for hygiene and skin barrier needs in medical settings; U-Pak combines wipes and foam for urinary and feminine hygiene, and Combat One targets military and first responders. The company differentiates itself with vertical integration and a proprietary platform, plus a long-standing presence in healthcare facilities and stability from a 2021 ownership transition to Hayfin Capital Management. Its goal is to grow and commercialize non-prescription topical therapeutics and hygiene products, expanding adoption across hospitals, long-term care facilities, and consumer channels while expanding product development and market reach.
Work here?Claim your company
Simplify's take
What believers are saying
- Theraworx pages were updated October and November 2026, signaling active merchandising and inventory support.
- Diabetic, joint, pain, and nerve products broaden basket size and cross-sell opportunities in 2026.
- Avadim retains a recognizable consumer brand after 2021 Hayfin ownership and Chapter 11 cleanup.
What critics are saying
- Stephen Woody and David Fann face a $1.77 million judgment from March 2025 litigation.
- Associated Industries Insurance still fights coverage in 2026, exposing Avadim to cash drains and distractions.
- A failed debt-fraud narrative can poison distributor trust and extinguish refinancing options by 2027.
What makes Avadim Health unique
- Theraworx still spans pain relief, diabetic care, and hygiene products across retail and institutional channels.
- Avadim controls formulation, manufacturing, and marketing, compressing iteration cycles versus outsourced brands.
- The 2026 product lineup shows active brand extension into nerve, joint, and diabetic use cases.
Help us improve and share your feedback! Did you find this helpful?